Dr. Grabowska is an Assistant Professor in the Department of Urology at Case Western Reserve University, with secondary appointments in Biochemistry and Pharmacology. Research in her laboratory is focused on understanding molecular mechanisms of prostate cancer progression. Currently, studies focus on how transcription factors, which bind to DNA and determine what genes are turned on or off, regulate prostate cancer. We are interested in how a specific transcription factor family, the nuclear factor I (NFI) family, interacts with androgen receptor, and how this interaction changes in response to prostate cancer therapy. Androgen receptor is the target of androgen deprivation therapy and the major therapeutic target in prostate cancer. Therefore, understanding how androgen receptor activity is regulated is critical for determining how patients fail androgen deprivation therapy. We are also interested in the androgen-independent roles of NFI family members, and how these can contribute to androgen receptor-independent prostate cancers. Our goal is to translate our basic science research into better outcomes for prostate cancer patients.
I am interested in the progression of prostate cancer from androgen-dependent to castrate-resistant prostate cancer. Although this progression can be achieved through multiple mechanisms, I am particularly interested in aberrant androgen receptor (AR) activation by dysregulation of co-factors (such as FOXA1 and nuclear factor I [NFI] family members) and the process of neuroendocrine differentiation following androgen-deprivation therapy and recurrence in advanced prostate cancer patients.